“I think that’s just wrong. First of all, we identified no specific safety signals, and probably the best evidence for that is that the FDA approved the drug in a record time of about 3 months with the broadest label possible,” Crooke said, referencing Ionis’ spinal muscular atrophy drug Spinraza. Crooke contended that Ionis is also welcoming transactions with a number of major health care players like Biogen ( BIIB ), GlaxoSmithKline (London Stock Exchange: GSK-GB), Novartis (Swiss Exchange: NOVN-CH), and Johnson & Johnson ( JNJ ). “I would say that it would be very difficult to make the case for those folks to invest knowing everything going on in the company if all of our drugs were going to fail and our toxicities were a big problem,” Crooke said. Meanwhile, it’s no secret retailers are struggling, which is why Jim Cramer thinks the market jumped on Five Below’s ( FIVE ) 1 percent same store sales growth, pushing the stock up over 10 percent on Thursday. The teen-targeting discount chain’s “fun and experiential” spirit is what helps it pull in shoppers even as the rest of its sector fails to do so, and what made its 1 percent growth shine in a low-bar environment, Cramer argued. And if you are worried about the risk of a potential border tax, the company even has a solution for that. “Even here there’s a glimmer of hope, as management believes there would be a low-dollar exemption for imports,” Cramer said. “If that’s the case, then Five Below will become one of the go-to names for retail in 2017.” Finally, Jim Cramer turned to technician and currencies expert Carly Garner’s charts for Green Rush a closer look at the euro, which looks poised to make a comeback.
To read more visit https://www.yahoo.com/news/cramer-remix-stock-could-spike-230027576.html